Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Nov 2021
Historique:
received: 04 10 2021
revised: 08 11 2021
accepted: 08 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 20 1 2022
Statut: epublish

Résumé

Liver cancer cell lines are frequently used in vitro tools to test candidate anti-cancer agents as well as to elucidate mechanisms of liver carcinogenesis. Among such mechanisms is cellular communication mediated by connexin-based gap junctions. The present study investigated changes in connexin expression and gap junction functionality in liver cancer in vitro. For this purpose, seven human liver cancer cell lines, as well as primary human hepatocytes, were subjected to connexin and gap junction analysis at the transcriptional, translational and activity level. Real-time quantitative reverse transcription polymerase chain reaction analysis showed enhanced expression of connexin43 in the majority of liver cancer cell lines at the expense of connexin32 and connexin26. Some of these changes were paralleled at the protein level, as evidenced by immunoblot analysis and in situ immunocytochemistry. Gap junctional intercellular communication, assessed by the scrape loading/dye transfer assay, was generally low in all liver cancer cell lines. Collectively, these results provide a full scenario of modifications in hepatocyte connexin production and gap junction activity in cultured liver cancer cell lines. The findings may be valuable for the selection of neoplastic hepatocytes for future mechanistic investigation and testing of anti-cancer drugs that target connexins and their channels.

Identifiants

pubmed: 34830068
pii: ijms222212187
doi: 10.3390/ijms222212187
pmc: PMC8623148
pii:
doi:

Substances chimiques

Connexin 43 0
Connexins 0
GJA1 protein, human 0
GJB2 protein, human 0
Connexin 26 127120-53-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : São Paulo Research Foundation
ID : 18/10953-9
Organisme : Fund for Scientific Research-Flanders
ID : G0F7219N
Organisme : National Council for Scientific and Technological Development
ID : 1270 310557/2019-4
Organisme : Coordenação de Aperfeicoamento de Pessoal de Nível Superior
ID : Brasil Finance code 001
Organisme : Alternatives Research and Development Foundation
Organisme : Center for Alternatives to Animal Testing at Johns Hopkins University-USA
Organisme : Flemish government
ID : Methusalem
Organisme : University Hospital of the Vrije Universiteit Brussel-Belgium
ID : Willy Gepts Fonds UZ-Brussel

Références

Oncotarget. 2016 Jan 12;7(2):2009-21
pubmed: 26655499
Int J Cancer. 1992 Jun 19;51(4):522-9
pubmed: 1318266
J Membr Biol. 2007 Jun;217(1-3):53-61
pubmed: 17665084
Biochim Biophys Acta. 2005 Dec 20;1719(1-2):6-23
pubmed: 16359940
Basic Clin Pharmacol Toxicol. 2017 Jan;120(1):30-37
pubmed: 27285124
Exp Mol Med. 2018 Jan 5;50(1):e419
pubmed: 29303513
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Circ Res. 1994 Jun;74(6):1050-7
pubmed: 7514508
Mol Carcinog. 2007 Apr;46(4):269-74
pubmed: 17295234
J Membr Biol. 2007 Aug;218(1-3):101-6
pubmed: 17978847
Hepatology. 1995 Jul;22(1):202-12
pubmed: 7601414
Int J Oncol. 2016 Mar;48(3):1205-17
pubmed: 26717856
Cancer Commun. 1990;2(1):21-31
pubmed: 1973356
PLoS One. 2014 Jan 27;9(1):e87293
pubmed: 24475266
Carcinogenesis. 1991 Sep;12(9):1701-6
pubmed: 1893531
Carcinogenesis. 2001 Oct;22(10):1593-600
pubmed: 11576997
Cancer Sci. 2012 May;103(5):860-7
pubmed: 22320152
Front Physiol. 2014 Jan 10;4:405
pubmed: 24454290
Gastroenterology. 2019 Sep;157(3):760-776
pubmed: 31063779
Hepatology. 1997 Mar;25(3):775-6
pubmed: 9049235
Cell Metab. 2019 Jan 8;29(1):18-26
pubmed: 30449681
Lab Invest. 1995 May;72(5):571-7
pubmed: 7745951
Prog Liver Dis. 1994;12:1-18
pubmed: 7746869
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Clin Exp Pathol. 2018 May 01;11(5):2931-2938
pubmed: 31938418
Cell Commun Adhes. 2015 Apr - Dec;22(2-6):29-37
pubmed: 27001459
Toxicol Pathol. 2000 Jul-Aug;28(4):540-7
pubmed: 10930040
Cancer Lett. 2007 Jul 18;252(2):208-15
pubmed: 17275998
Transl Res. 2015 Oct;166(4):332-43
pubmed: 26051630
Front Physiol. 2014 Jun 27;5:237
pubmed: 25018732
Hepatology. 2019 Mar;69(3):1317-1323
pubmed: 30300925
Cancer Manag Res. 2019 May 31;11:5133-5146
pubmed: 31213923
Oncol Rep. 2014 Feb;31(2):540-50
pubmed: 24317203
Sci Rep. 2017 Aug 15;7(1):8268
pubmed: 28811572
Cytotherapy. 2014 Jun;16(6):800-9
pubmed: 24642019
Proc Natl Acad Sci U S A. 1983 Feb;80(3):755-9
pubmed: 6298773
EXCLI J. 2016 Feb 25;15:177-86
pubmed: 27065778
Eur J Cell Biol. 1987 Feb;43(1):48-54
pubmed: 3032632
J Exp Clin Cancer Res. 2019 Apr 4;38(1):145
pubmed: 30947731
Lab Invest. 1993 Aug;69(2):210-6
pubmed: 8394478
Cancers (Basel). 2010 Jul 07;2(3):1441-52
pubmed: 24281167
Asian Pac J Cancer Prev. ;18(9):2329-2337
pubmed: 28950674
Mol Carcinog. 1990;3(5):273-8
pubmed: 2173931
Cardiovasc Res. 2000 Mar;45(4):941-51
pubmed: 10728420
Eur J Cell Biol. 1992 Oct;59(1):21-6
pubmed: 1334833
J Cell Sci. 1994 Jan;107 ( Pt 1):83-95
pubmed: 8175925
Oncotarget. 2017 Jun 29;8(38):63620-63634
pubmed: 28969016
Cell Immunol. 2007 Jun;247(2):103-10
pubmed: 17900549
Int J Oncol. 2018 Mar;52(3):872-880
pubmed: 29393359
Biochim Biophys Acta. 2016 Jun;1862(6):1111-21
pubmed: 26912412
Medicina (Kaunas). 2019 Aug 23;55(9):
pubmed: 31450841
World J Gastroenterol. 2004 Oct 1;10(19):2785-90
pubmed: 15334670
Biophys J. 2010 May 19;98(9):1809-19
pubmed: 20441744
Front Public Health. 2018 Sep 11;6:261
pubmed: 30255008
Carcinogenesis. 1999 Mar;20(3):401-6
pubmed: 10190553
Arch Toxicol. 1999 Sep;73(7):373-80
pubmed: 10550479
Int J Mol Sci. 2020 Sep 07;21(18):
pubmed: 32906817
Glia. 2009 Feb;57(3):258-69
pubmed: 18837047
Am J Physiol. 1992 Nov;263(5 Pt 1):G650-8
pubmed: 1332499
Gastroenterology. 2005 Feb;128(2):433-48
pubmed: 15685554
PLoS One. 2021 Feb 4;16(2):e0245939
pubmed: 33539378
Biomed Pharmacother. 2017 Nov;95:1844-1852
pubmed: 28968929
Endocrinology. 2005 Apr;146(4):2048-54
pubmed: 15618352
Cells. 2019 Aug 14;8(8):
pubmed: 31416286
Am J Physiol. 1995 Feb;268(2 Pt 1):C356-65
pubmed: 7532358
Curr Drug Metab. 2006 Aug;7(6):629-60
pubmed: 16918317
Int J Oncol. 2016 Feb;48(2):703-13
pubmed: 26648344
Gastroenterology. 2017 Mar;152(4):745-761
pubmed: 28043904
Shock. 2000 Jul;14(1):53-9
pubmed: 10909894
Pflugers Arch. 1995 Nov;431(1):138-40
pubmed: 8584413
Oncotarget. 2015 Apr 30;6(12):10116-33
pubmed: 25426556
J Hepatol. 2019 Apr;70(4):759-772
pubmed: 30599172
Asian Pac J Cancer Prev. 2015;16(18):8271-9
pubmed: 26745072
PLoS One. 2014 Oct 22;9(10):e110744
pubmed: 25338121
Am J Physiol. 1999 May;276(5):R1249-57
pubmed: 10233014
J Biol Chem. 1985 Mar 10;260(5):3097-107
pubmed: 3972818
J Cell Physiol. 1996 Feb;166(2):461-7
pubmed: 8592007
Int J Cancer. 1994 Jan 2;56(1):87-94
pubmed: 8262683
World J Hepatol. 2017 Jan 28;9(3):119-125
pubmed: 28217247

Auteurs

Kaat Leroy (K)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Cícero Júlio Silva Costa (CJ)

Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva 87, Cidade Universitária, São Paulo 05508-270, Brazil.

Alanah Pieters (A)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Bruna Dos Santos Rodrigues (B)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Raf Van Campenhout (R)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Axelle Cooreman (A)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Andrés Tabernilla (A)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Bruno Cogliati (B)

Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva 87, Cidade Universitária, São Paulo 05508-270, Brazil.

Mathieu Vinken (M)

Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH